|
RAB6A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.45860023848377E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.97340000188618E-08 |
| Normal-vs-Stage2 |
3.418300E-04 |
| Normal-vs-Stage3 |
4.95048446680357E-12 |
| Normal-vs-Stage4 |
5.13989995010178E-09 |
| Stage1-vs-Stage2 |
6.132000E-01 |
| Stage1-vs-Stage3 |
4.084500E-03 |
| Stage1-vs-Stage4 |
4.214100E-02 |
| Stage2-vs-Stage3 |
1.764240E-02 |
| Stage2-vs-Stage4 |
5.804200E-02 |
| Stage3-vs-Stage4 |
9.085200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.3263948807114E-11 |
| Normal-vs-AfricanAmerican |
4.0590000000007E-05 |
| Normal-vs-Asian |
3.62690000033083E-07 |
| Caucasian-vs-AfricanAmerican |
8.823200E-01 |
| Caucasian-vs-Asian |
6.475400E-01 |
| AfricanAmerican-vs-Asian |
8.519200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.57759999403129E-09 |
| Normal-vs-Female |
2.93360002956433E-09 |
| Male-vs-Female |
4.009000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.32490000004371E-06 |
| Normal-vs-Age(41-60Yrs) |
5.54399859353794E-11 |
| Normal-vs-Age(61-80Yrs) |
4.60850024808224E-10 |
| Normal-vs-Age(81-100Yrs) |
6.23770000000023E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.163600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.598100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.972100E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.413800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.645400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.617400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.386600E-01 |
| Classical-VS-Follicular |
5.087400E-01 |
| Classical-VS-Other |
3.010400E-01 |
| Classical-VS-Normal |
3.5881999593812E-09 |
| Tall-VS-Follicular |
5.972300E-02 |
| Tall-VS-Other |
7.511400E-01 |
| Tall-VS-Normal |
8.56499999812854E-08 |
| Follicular-VS-Other |
3.085200E-01 |
| Follicular-VS-Normal |
5.77429999999435E-05 |
| Other-VS-Normal |
9.200400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.96119964291609E-10 |
| Normal-vs-N1 |
9.6773999924693E-09 |
| N0-vs-N1 |
2.685200E-01 |
|
|
